A personalized anti-cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella
Ylosmaki, E.; Fusciello, M.; Uoti, A.; Feola, S.; Martins, B.; Aalto, K.; Hamdan, F.; Ciaro, J.; Viitala, T.; Cerullo, V.
Show abstract
Common vaccines for infectious diseases have been repurposed as cancer immunotherapies. Intratumoural administration of these repurposed vaccines can induce immune cell infiltration into the treated tumour. Here, we have used an approved trivalent live attenuated measles, mumps, and rubella (MMR) vaccine in our previously developed PeptiENV anti-cancer vaccine platform. Intratumoural administration of this novel MMR-containing PeptiENV anti-cancer vaccine significantly increased both intratumoural as well as systemic tumour-specific T cell responses. In addition, PeptiENV therapy, in combination with immune checkpoint inhibitor therapy, significantly improved tumour growth control and survival as well as increased the number of mice responsive to immune checkpoint inhibitor therapy.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin 99%
- Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma 96%
- Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling. 95%
Similar papers in this journal
- Polymeric Pathogen-like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A Virus 95%
- A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta 94%
- Virus-like particles (VLPs) are efficient tools for boosting mRNA-induced antibodies 94%
Similar papers in this journal
- mRNA-based vaccine candidate COReNAPCIN(R) induces robust humoral and cellular immunity in mice and non-human primates 95%
- Novel Oral Adjuvant to Enhance Cytotoxic Memory-Like NK Cell Responses in an HIV Vaccine Platform 95%
- PF-D-Trimer, a broadly protective SARS-CoV-2 subunit vaccine: immunogenicity and application 95%
Similar papers in this journal
- A Gamma-adapted recombinant subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection. 95%
- Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates 94%
- Protective mucosal immunity against SARS-CoV-2 after heterologous systemic RNA-mucosal adenoviral vector immunization 93%
Similar papers in this journal
- Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2 95%
- Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity 94%
- Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines for SARS-CoV-2 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.